SARS-CoV-2 vaccines in development

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Origin and evolution of pathogenic coronaviruses

Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,539 · see citing works

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,908 · see citing works

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) · doi:10.1101/2020.03.17.20037713 · Cited by 1,769 · see citing works

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · see citing works

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504 · see citing works

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434 · see citing works

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,303 · see citing works

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303 · see citing works

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · see citing works

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · see citing works

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

(2020) · Science · doi:10.1101/2020.07.14.20151126 · Cited by 1,192 · see citing works

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156 · see citing works

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126 · see citing works

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055 · see citing works

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion ConformationPreprint

Wrapp, D., Wang, N., Corbett, K. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.11.944462 · Cited by 1,010 · see citing works

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Imai, M., Iwatsuki‐Horimoto, K., Hatta, M., Loeber, S. J., Halfmann, P., Nakajima, N., Watanabe, T., Ujie, M., Takahashi, K., Ito, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009799117 · Cited by 977 · see citing works

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · see citing works

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Kim, Y., Kim, S.-G., Kim, S.-M., Kim, E.-H., Park, S.-J., Yu, K.-M., Chang, J.-H., Kim, E. J., Lee, S., Casel, M. A. B., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.023 · Cited by 883 · see citing works

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822 · see citing works

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

Structural insights into coronavirus entry

(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769 · see citing works

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.

Xia, S., Duan, K., Zhang, Y.-T., Zhao, D.-Y., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y.-B., Zhang, W., et al. (2020) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2020.15543 · Cited by 765 · see citing works

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762 · see citing works

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748 · see citing works

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720 · see citing works

SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway

Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., & Jiang, C. (2008) · Cell Research · doi:10.1038/cr.2008.15 · Cited by 700 · see citing works

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Williamson, B. N., Feldmann, F., Schwarz, B. H., Meade-White, K. D., Porter, D., Schulz, J. E., van Doremalen, N., Leighton, I. A., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2423-5 · Cited by 696 · see citing works

A decade after SARS: strategies for controlling emerging coronaviruses

Graham, R. L., Donaldson, E., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 676 · see citing works

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675 · see citing works

Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event

Vijgen, L., Keyaerts, E., Moës, E., Thoelen, I., Wollants, E., Lemey, P., Vandamme, A., & Ranst, M. A. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1595-1604.2005 · Cited by 590 · see citing works

Structure-based Design of Prefusion-stabilized SARS-CoV-2 SpikesPreprint

Hsieh, C., Goldsmith, J., Schaub, J. M., et al. (2020) · bioRxiv · doi:10.1101/2020.05.30.125484 · Cited by 588 · see citing works

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Jiang, R.-D., Liu, M.-Q., Chen, Y., Shan, C., Zhou, Y.-W., Shen, X.-R., Li, Q., Zhang, L., Zhu, Y., Si, H.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.027 · Cited by 541 · see citing works

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525 · see citing works

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501 · see citing works

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · see citing works

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., McCune, B. T., Fox, J. M., Chen, R. E., Alsoussi, W. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.011 · Cited by 477 · see citing works

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440 · see citing works

SARS-CoV-2 is transmitted via contact and via the air between ferrets

Richard, M., Kok, A., de Meulder, D., Bestebroer, T. M., Lamers, M. M., Okba, N. M. A., van Vlissingen, M. F., Rockx, B., Haagmans, B. L., Koopmans, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17367-2 · Cited by 438 · see citing works

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Sun, J., Zhuang, Z., Zheng, J. H., Li, K., Wong, R. L.-Y., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.010 · Cited by 434 · see citing works

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Wang, S., Tseng, S., Yen, C., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F., Liu, W.-T., Chen, Y. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421 · see citing works

Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2

Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y., et al. (2020) · doi:10.1101/2020.03.13.990226 · Cited by 419 · see citing works

Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life

Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 403 · see citing works

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

Laczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 366 · see citing works

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach

Talon, J., Salvatore, M., O’Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., García‐Sastre, A., & Palese, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070525997 · Cited by 320 · see citing works

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 297 · see citing works

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

Agrawal, A. S., Tao, X., Algaissi, A. A., Garron, T. M., Narayanan, K., Peng, B., Couch, R. B., & Tseng, C.-T. K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1177688 · Cited by 274 · see citing works

Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants

Deming, D., Sheahan, T. P., Heise, M. T., Yount, B. L., Davis, N., Sims, A. M., Suthar, M. S., Harkema, J. R., Whitmore, A. C., Pickles, R. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 272 · see citing works

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.026 · Cited by 267 · see citing works

COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva

Pisanic, N., Randad, P., Kruczynski, K., Manabe, Y. C., Thomas, D. L., Pekosz, A., Klein, S., Betenbaugh, M. J., Clarke, W., Laeyendecker, O., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02204-20 · Cited by 244 · see citing works

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Shan, C., Yao, Y., Yang, X., Zhou, Y., Gao, G., Peng, Y., Yang, L., Hu, X., Xiong, J., Jiang, R.-D., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0364-z · Cited by 241 · see citing works

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Guebre-Xabier, M., Patel, N., Tian, J.-H., Zhou, B., Maciejewski, S., Lam, K., Portnoff, A. D., Massare, M. J., Frieman, M. B., Piedra, P. A., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.064 · Cited by 231 · see citing works

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224 · see citing works

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

McElhaney, J. E., Ewen, C., Zhou, X., Kane, K. P., Xie, D., Hager, W. D., Barry, M. B., Kleppinger, A., Wang, Y., & Bleackley, R. C. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.136 · Cited by 219 · see citing works

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro

Kam, Y., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., Chu, S. L., Tse, J., Guarner, J., Zaki, S. R., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.011 · Cited by 209 · see citing works

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

Rathnasinghe, R., Strohmeier, S., Amanat, F., Gillespie, V., Krammer, F., García‐Sastre, A., Coughlan, L., Schotsaert, M., & Uccellini, M. B. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1838955 · Cited by 197 · see citing works

Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice

Case, J., Rothlauf, P. W., Chen, R. E., Kafai, N. M., Fox, J., Smith, B. K., Shrihari, S., McCune, B. T., Harvey, I. B., Keeler, S. P., et al. (2020) · Cell Host and Microbe · doi:10.1016/j.chom.2020.07.018 · Cited by 184 · see citing works

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181 · see citing works

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.033 · Cited by 180 · see citing works

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2Preprint

Williamson, B. N., Feldmann, F., Schwarz, B. H., Meade-White, K. D., Porter, D., Schulz, J. E., van Doremalen, N., Leighton, I. A., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.15.043166 · Cited by 180 · see citing works

Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine

Lin, J., Zhang, J., Su, N., Xu, J., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200702 · Cited by 168 · see citing works

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Su, F., Patel, G. B., Hu, S., & Chen, W. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1114195 · Cited by 161 · see citing works

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

Lu, J., Lu, G., Tan, S., Jia Hui, X. I. A., Xiong, H., Yu, X., Qi, Q., Yu, X., Li, L., Yu, H., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00392-7 · Cited by 147 · see citing works

Dynamics and significance of the antibody response to SARS-CoV-2 infectionPreprint

Iyer, A., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M. V., Slater, D., Mills, R., Teng, E., Kamruzzaman, M., Garcia-Beltran, W., et al. (2020) · medRxiv · doi:10.1101/2020.07.18.20155374 · Cited by 143 · see citing works

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Graham, S., McLean, R., Spencer, A. J., Belij-Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J., Hayes, J. W. P., Martini, V., Thakur, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00221-3 · Cited by 126 · see citing works

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009–2010 season

DiazGranados, C. A., Dunning, A. J., Jordanov, E., Landolfi, V. A., Denis, M., & Talbot, H. K. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.013 · Cited by 123 · see citing works

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

Sun, W., Leist, S. R., McCroskery, S., Liu, Y., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K. H., García‐Sastre, A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103132 · Cited by 113 · see citing works

Immunoglobulin G and Its Function in the Human Respiratory Tract

Reynolds, H. Y. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)64949-0 · Cited by 112 · see citing works

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Chen, W., Tao, X., Agrawal, A. S., Algaissi, A. A., Peng, B., Pollet, J. B. K., Strych, U., Bottazzi, M. E., Hotez, P. J., Lustigman, S., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.061 · Cited by 102 · see citing works

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

Dunning, A. J., DiazGranados, C. A., Voloshen, T., Hu, B. T., Landolfi, V. A., & Talbot, H. K. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00604-15 · Cited by 101 · see citing works

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical TrialPreprint

Zhang, Y., Zeng, G., Pan, H., et al. (2020) · medRxiv · doi:10.1101/2020.07.31.20161216 · Cited by 96 · see citing works

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Sun, W., McCroskery, S., Liu, W., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., et al. (2020) · Vaccines · doi:10.3390/vaccines8040771 · Cited by 92 · see citing works

Expression of Homing Receptors on IgA1 and IgA2 Plasmablasts in Blood Reflects Differential Distribution of IgA1 and IgA2 in Various Body Fluids

Pakkanen, S. H., Kantele, J. M., Moldoveanu, Z., Hedges, S. R., Häkkinen, M., Mestecky, J. F., & Kantele, A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00475-09 · Cited by 91 · see citing works

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

Houser, K. V., Broadbent, A., Gretebeck, L., Vogel, L., Lamirande, E. W., Sutton, T. C., Bock, K. W., Minai, M., Orandle, M. S., Moore, I. N., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006565 · Cited by 88 · see citing works

Direct visualization of translational GTPase factor pool formed around the archaeal ribosomal P-stalk by high-speed AFM

Imai, H., Uchiumi, T., & Kodera, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018975117 · Cited by 88 · see citing works

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., García‐Sastre, A., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.02648-20 · Cited by 82 · see citing works

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaPreprint

Randad, P. R., Pisanic, N., Kruczynski, K. L., et al. (2020) · medRxiv · doi:10.1101/2020.05.24.20112300 · Cited by 80 · see citing works

Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets

Broadbent, A. J., Santos, C. P., Anafu, A., Wimmer, E., Mueller, S., & Subbarao, K. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.11.054 · Cited by 79 · see citing works

SARS-CoV-2 is transmitted via contact and via the air between ferretsPreprint

Richard, M., Kok, A., de Meulder, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.16.044503 · Cited by 66 · see citing works

Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques

Song, T., 昆明650223，中国, 中.-C., Zheng, H., Han, J.-B., Jin, L., Yang, X. S., Liu, F., Luo, R., Tian, R., Cai, H., et al. (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.202 · Cited by 62 · see citing works

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 InfectionPreprint

Rathnasinghe, R., Strohmeier, S., Amanat, F., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.06.190066 · Cited by 56 · see citing works

Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patientsPreprint

Isho, B., Abe, K. T., Zuo, M., et al. (2020) · medRxiv · doi:10.1101/2020.08.01.20166553 · Cited by 54 · see citing works

Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique

Robinson, G., Sellers, E. M., & Janecek, E. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.129 · Cited by 43 · see citing works

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccinePreprint

Keech, C. A., Glenn, G. M., Albert, G. R., et al. (2020) · medRxiv · doi:10.1101/2020.08.05.20168435 · Cited by 43 · see citing works

Receptor-binding domain of SARS-Cov spike protein: Soluble expression inE.coli, purification and functional characterization

Chen, J. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i39.6159 · Cited by 40 · see citing works

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccinePreprint

Sun, W., McCroskery, S., Liu, W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.30.229120 · Cited by 40 · see citing works

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune EnhancementPreprint

Chen, W., Tao, X., Agrawal, A. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.098079 · Cited by 38 · see citing works

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challengePreprint

Guebre‐Xabier, M., Patel, N., Tian, J.-H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.18.256578 · Cited by 34 · see citing works

Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms

Luke, C. J., & Subbarao, K. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.922416 · Cited by 29 · see citing works

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection

Mohandas, S., Jain, R., Yadav, P. D., Shete-Aich, A., Sarkale, P., Kadam, M., Kumar, A., Deshpande, G. R., Baradkar, S., Patil, S., et al. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_2235_20 · Cited by 26 · see citing works

[Effects of noise and vibration during embryogenesis on fetal development and postnatal growth of the mouse].

Briese, V., Fanghänel, J., Briese, A., & Gasow, H. (1982) · PubMed · Cited by 22 · see citing works

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse modelPreprint

Amanat, F., Strohmeier, S., Rathnasinghe, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.16.300970 · Cited by 22 · see citing works

A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2

Rohaim, M. A., & Munir, M. (2020) · Vaccines · doi:10.3390/vaccines8030472 · Cited by 20 · see citing works

Evaluation of Risks and Benefits Associated with Vaccination against Coronavirus Infections in Cats

Scott, F. W. (1999) · Advances in veterinary medicine · doi:10.1016/s0065-3519(99)80026-3 · Cited by 14 · see citing works

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19Preprint

Graham, S. P., McLean, R. K., Spencer, A. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.20.159715 · Cited by 13 · see citing works

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidatePreprint

Sun, W., Leist, S. R., McCroskery, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.26.221861 · Cited by 11 · see citing works

Receptor-binding domain of SARS-Cov spike protein： Soluble expression in E.coli,purification and functional characterization

Jing, J., Chen, Lin, Miao, M., Jiaming, Li, ‡., Yan-ying, Qingyu, Zhu, Z., Changlin, et al. (2005) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3 · see citing works

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · see citing works

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397 · see citing works

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

Adaptive immunity to SARS-CoV-2 and COVID-19

Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860 · see citing works

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504 · see citing works

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343 · see citing works

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.037 · Cited by 992 · see citing works

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01429-x · Cited by 898 · see citing works

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696 · see citing works

Neutralizing monoclonal antibodies for treatment of COVID-19

Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732 · see citing works

COVID-19 vaccines: where we stand and challenges ahead

on behalf of the COVID-19 Commission of Accademia Nazionale dei Lincei, R., Forni, G., & Mantovani, A. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00720-9 · Cited by 762 · see citing works

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775 · see citing works

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

Zhang, J., Dong, X., Liu, G., & Gao, Y. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08921-5 · Cited by 733 · see citing works

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex

Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630 · see citing works

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Gray, K. J., Bordt, E. A., Atyeo, C., Deriso, E., Akinwunmi, B., Young, N., Baez, A. M., Shook, L. L., Cvrk, D., James, K., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.03.023 · Cited by 699 · see citing works

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583 · see citing works

Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants

Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636 · see citing works

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Anderson, R. M., Vegvari, C., Truscott, J., & Collyer, B. S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32318-7 · Cited by 529 · see citing works

The role of vaccines in combatting antimicrobial resistance

Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 504 · see citing works

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371 · see citing works

The first 12 months of COVID-19: a timeline of immunological insights

Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 448 · see citing works

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2103154118 · Cited by 187 · see citing works

COVID-19 vaccine development: milestones, lessons and prospects

Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 448 · see citing works

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Zhang, J., Cai, Y., Xiao, T., Lu, J., Peng, H., Sterling, S. M., Walsh, R. M., Rits‐Volloch, S., Zhu, H., Woosley, A. N., et al. (2021) · Science · doi:10.1126/science.abf2303 · Cited by 402 · see citing works

BNT162b2 mRNA COVID-19 Vaccine: First Approval

Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01480-7 · Cited by 424 · see citing works

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410 · see citing works

Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection

Tali, S. H. S., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi‐Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 411 · see citing works

COVID-19 vaccines: rapid development, implications, challenges and future prospects

Kashte, S., Gulbake, A., El‐Amin, S. F., & Gupta, A. (2021) · Human Cell · doi:10.1007/s13577-021-00512-4 · Cited by 404 · see citing works

Maintaining safety with SARS-CoV-2 vaccines

Castells, M. C., & Phillips, E. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2035343 · Cited by 395 · see citing works

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine

Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., Csernalabics, B., Lang-Meli, J., Janowska, I., Staniek, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03841-4 · Cited by 391 · see citing works

Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination

Tang, J., Zeng, C., Cox, T. M., Li, C., Son, Y. M., Cheon, I. S., Wu, Y., Behl, S., Taylor, J. J., Chakaraborty, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.add4853 · Cited by 358 · see citing works

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. A. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 345 · see citing works

Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery

Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 349 · see citing works

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Arunachalam, P. S., Walls, A. C., Golden, N., Atyeo, C. G., Fischinger, S., Li, C., Aye, P. P., Navarro, M. J., Lai, L., Edara, V. V., et al. (2021) · Nature · doi:10.1038/s41586-021-03530-2 · Cited by 326 · see citing works

COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies

Salian, V. S., Wright, J. A., Vedell, P. T., Nair, S. A., Li, C., Kandimalla, M., Tang, X., Carmona, E. M., Kalari, K. R., & Kandimalla, K. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00608 · Cited by 319 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265 · see citing works

Structural biology of SARS-CoV-2: open the door for novel therapies

Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 293 · see citing works

Role of nanotechnology behind the success of mRNA vaccines for COVID-19

Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., Chhabra, D., Joshi, K., & Bharani, K. K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101142 · Cited by 286 · see citing works

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of <i>in vivo</i> imaging

Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282 · see citing works

The evolution and future of influenza pandemic preparedness

Harrington, W. N., Kackos, C. M., & Webby, R. J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00603-0 · Cited by 282 · see citing works

SARS-CoV-2 escape <i>in vitro</i> from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond

Bettini, E., & Locci, M. (2021) · Vaccines · doi:10.3390/vaccines9020147 · Cited by 283 · see citing works

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2020) · doi:10.1101/2020.12.17.423313 · Cited by 258 · see citing works

mRNA Vaccines in the COVID-19 Pandemic and Beyond

Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 252 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

(2021) · doi:10.1371/journal.ppat.1009453 · Cited by 258 · see citing works

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L., & Annunziato, F. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00359-2 · Cited by 246 · see citing works

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0755 · Cited by 262 · see citing works

Humoral Responses and Serological Assays in SARS-CoV-2 Infections

Galipeau, Y., Greig, M., Liu, G., Driedger, M., & Langlois, M.-A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610688 · Cited by 225 · see citing works

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Martínez-Flores, D., Zepeda–Cervantes, J., Cruz-Reséndiz, A., Aguirre‐Sampieri, S., Sampieri, A., & Vaca, L. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701501 · Cited by 237 · see citing works

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D. A., & Yu, H. (2021) · BMC Medicine · doi:10.1186/s12916-021-02059-5 · Cited by 241 · see citing works

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

Català, A., Muñoz‐Santos, C., Galván‐Casas, C., Riesco, M. R., Revilla‐Nebreda, D., Truyols, A. S., Giavedoni, P., Llamas‐Velasco, M., González‐Cruz, C., Cubiró, X., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20639 · Cited by 239 · see citing works

Structure of SARS-CoV-2 spike protein

Zhang, J., Xiao, T., Cai, Y., & Chen, B. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.08.010 · Cited by 237 · see citing works

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Rotshild, V., Raccah, B. H., Miskin, I. N., Muszkat, M., & Matok, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-02321-z · Cited by 224 · see citing works

mRNA vaccines for infectious diseases — advances, challenges and opportunities

Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 246 · see citing works

Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ^® Analog by In Vitro Transcription

Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E. (2021) · Current Protocols · doi:10.1002/cpz1.39 · Cited by 231 · see citing works

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 216 · see citing works

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Chavda, V. P., Vora, L. K., Pandya, A., & Patravale, V. B. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.021 · Cited by 212 · see citing works

The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics

Wu, W., Cheng, Y., Zhou, H. W., Sun, C., & Zhang, S. (2023) · Virology Journal · doi:10.1186/s12985-023-01968-6 · Cited by 213 · see citing works

The glycosylation in SARS-CoV-2 and its receptor ACE2

Gong, Y., Qin, S., Dai, L., & Tian, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00809-8 · Cited by 207 · see citing works

Overview of SARS-CoV-2 infection in adults living with HIV

Ambrosioni, J., Blanco, J. L., Reyes‐Urueña, J., Davies, M., Sued, O. G., Marcos, M. Á., Martínez, E., Bertagnolio, S., Alcamı́, J., Miró, J. M., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00070-9 · Cited by 206 · see citing works

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Cornberg, M., Buti, M., Eberhardt, C. S., Grossi, P., & Shouval, D. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.032 · Cited by 206 · see citing works

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

Zhou, P.-P., Yuan, M., Song, G., Beutler, N., Shaabani, N., Huang, D.-L., He, W.-T., Zhu, X.-Y., Callaghan, S., Yong, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9215 · Cited by 132 · see citing works

A critical overview of computational approaches employed for COVID-19 drug discovery

Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206 · see citing works

Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale

Amman, F., Markt, R., Endler, L., Hupfauf, S., Agerer, B., Schedl, A., Richter, L., Zechmeister, M., Bicher, M., Heiler, G., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01387-y · Cited by 203 · see citing works

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Clark, S., Clark, L., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M., Regan, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.027 · Cited by 176 · see citing works

Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations

Kounis, N. G., Koniari, I. C., GREGORIO, C. D., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S. F., Gogos, C., Kouni, S. N., Kounis, G. N., et al. (2021) · Vaccines · doi:10.3390/vaccines9030221 · Cited by 192 · see citing works

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies

Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 186 · see citing works

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

Grainger, R., Kim, A. H. J., Conway, R. P., Yazdany, J., & Robinson, P. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00755-x · Cited by 185 · see citing works

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays

Perkmann, T., Perkmann‐Nagele, N., Köller, T., Mucher, P., Radakovics, A., Marculescu, R., Wolzt, M., Wagner, O. F., Binder, C. J., & Haslacher, H. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00247-21 · Cited by 181 · see citing works

A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV‑2 in Mice

Powell, A. E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P. A. B., Li, S., Pham, T. D., Pak, J. E., Chiu, W., & Kim, P. S. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01405 · Cited by 174 · see citing works

Nanovaccines: A game changing approach in the fight against infectious diseases

Priyanka, Abusalah, M. A. H., Chopra, H., Sharma, A., Mustafa, S. A., Choudhary, O. P., Sharma, M. K., Dhawan, M. K., Khosla, R., Loshali, A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115597 · Cited by 181 · see citing works

A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19

Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000970 · Cited by 180 · see citing works

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Siegel, C. A., MELMED, G. Y., McGovern, D. P. B., Rai, V., Krammer, F., Rubin, D. T., Abreu, M. T., & Dubinsky, M. C. (2021) · Gut · doi:10.1136/gutjnl-2020-324000 · Cited by 179 · see citing works

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021) · Cell Host and Microbe · doi:10.1016/j.chom.2021.03.008 · Cited by 188 · see citing works

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

(2022) · doi:10.1016/j.cell.2022.01.027 · Cited by 179 · see citing works

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E., Hadi, H. A., & Sultan, A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631139 · Cited by 177 · see citing works

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.04.015 · Cited by 153 · see citing works

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro

Pasquereau, S., Nehme, Z., Ahmad, S. H., Daouad, F., Assche, J. V., Wallet, C., Schwartz, C., Rohr, O., Morot-Bizot, S., & Herbein, G. (2021) · Viruses · doi:10.3390/v13020354 · Cited by 177 · see citing works

An overview of current COVID-19 vaccine platforms

Nagy, A., & Alhatlani, B. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.061 · Cited by 151 · see citing works

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 167 · see citing works

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses

Nambulli, S., Xiang, Y., Tilston-Lunel, N. L., Rennick, L., Sang, Z., Klimstra, W., Reed, D., Crossland, N., Shi, Y., & Duprex, W. P. (2021) · Science Advances · doi:10.1126/sciadv.abh0319 · Cited by 135 · see citing works

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 187 · see citing works

Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia

MacIntyre, C. R., Costantino, V., & Trent, M. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.042 · Cited by 166 · see citing works

The known unknowns of T cell immunity to COVID-19

Karlsson, A. C., Humbert, M., & Buggert, M. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe8063 · Cited by 165 · see citing works

CD8 + T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19

Mallajosyula, V. V. A., Ganjavi, C., Chakraborty, S., McSween, A. M., Pavlovitch-Bedzyk, A. J., Wilhelmy, J., Nau, A. N., Manohar, M., Nadeau, K. C., & Davis, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg5669 · Cited by 161 · see citing works

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients

Li, Y., Ma, M., Lei, Q., Wang, F., Hong, W., Lai, D., Hou, H., Xu, Z., Zhang, B., Chen, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108915 · Cited by 163 · see citing works

T Cell Memory: Understanding COVID-19

Jarjour, N. N., Masopust, D., & Jameson, S. C. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.009 · Cited by 158 · see citing works

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F. R., Davies, H. D., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00080 · Cited by 149 · see citing works

Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation

Jawad, B., Adhikari, P., Podgornik, R., & Ching, W. Y. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00560 · Cited by 148 · see citing works

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

Bueno, S. M., Abarca, K., V, González, P. A., Gálvez, N. M. S., Soto, J. A., Duarte, L. F., Schultz, B. M., Pacheco, G. A., González, L. A., Vázquez, Y., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab823 · Cited by 148 · see citing works

mRNA vaccine in cancer therapy: Current advance and future outlook

Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 152 · see citing works

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice

Pang, N. Y.-L., Pang, A. S.-R., Chow, V. T. K., & Wang, D.-Y. (2021) · Military Medical Research · doi:10.1186/s40779-021-00342-3 · Cited by 124 · see citing works

COVID‐19 vaccinations: The unknowns, challenges, and hopes

Mohamed, K., Rzymski, P., Islam, M. S., Makuku, R., Mushtaq, A., Khan, A., Ivanovska, M., Makka, S. A., Hashem, F., Marquez, L. P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27487 · Cited by 142 · see citing works

Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy

Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 141 · see citing works

Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality

Patel, M. D., Rosenstrom, E., Ivy, J. S., Mayorga, M. E., Keskinocak, P., Boyce, R. M., Lich, K. H., Smith, R., Johnson, K., Delamater, P. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.10782 · Cited by 136 · see citing works

An interactive website tracking COVID-19 vaccine development

Shrotri, M., Swinnen, T., Kampmann, B., & Parker, E. P. K. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00043-7 · Cited by 139 · see citing works

COVID-19: Rethinking the Lockdown Groupthink

Joffe, A. R. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.625778 · Cited by 153 · see citing works

Viral Vaccines and Current Status of Vaccine Developing Studies Against Novel SARS Coronavirus-2

Keşli, R. (2020) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2020.84755

SARS-CoV-2 Vaccine Development: An Overview and Perspectives

Liu, Y., Wang, K., Massoud, T., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 25 · see citing works

Phase III Vaccines for SARS-CoV-2: A Review of Development and Available Data

Ehsan, H. S. A., Sana, M. K., Sarwar, A., Hanif, N., & Khan, S. R. (2020) · Internal Medicine Review · doi:10.18103/imr.v6i5.905

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Alturki, S. O., Alturki, S. O., Connors, J. R., Cusimano, G. M., Kutzler, M. A., Izmirly, A. M., & Haddad, E. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01880 · Cited by 73 · see citing works

Latest in COVID-19 Vaccine 'Candidates' Race

Atoum, M. F. M., Zreig, D. A., & Zreig, L. M. A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220818124416